

## Trastuzumab Cardiotoxicity in Patients with Breast Cancer

Aguinaldo Figueiredo Freitas Jr. e Salvador Rassi

Departamento de Cardiologia, Faculdade de Medicina da Universidade Federal de Goiás, Goiânia, GO - Brazil

### Dear Editor,

We read the article "Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer"<sup>1</sup>. Cardio-oncology is a current challenge for cardiologists, due to the high prevalence of cardiovascular toxicity secondary to chemotherapy agents, in addition to the need to determine effective measures to reduce the incidence of that complication<sup>2-4</sup>.

The above-cited article is extremely relevant and we would like to congratulate its authors. Its title and objective lead us immediately to believe that a method capable of early detecting subclinical cardiotoxicity (defined as a reduction in

ventricular ejection fraction) would be described. However, we could not understand how the authors assumed that the change in diastolic function found preceded systolic dysfunction, because none of the patients studied showed a significant reduction in ventricular ejection fraction in the three-month follow-up. We would like to ask the authors if they attribute the lack of ejection fraction reduction to the short follow-up, to the lack of previous cardiac changes (coronary artery disease, cerebral vascular accident or heart failure), or to the fact that the prevalence of comorbidities (arterial hypertension and diabetes) in the population studied was lower than that reported in the large studies.

Thank you and congratulations for your article.

### Keywords

Immunosuppressive Agents; Breast Neoplasms / adverse effects; Antineoplastic Agents / adverse effects; Heart Failure; Ventricular Dysfunction.

### Mailing Address: Aguinaldo Figueiredo Freitas Jr. •

Rua T-51, 964, ap. 1902, Bueno – Postal Code 74215-210, Goiânia, GO, Brazil

E-mail: affreitasjr@cardiol.br, affreitasjr@msn.com

Manuscript received August 10, 2013; revised manuscript October 04, 2013;

accepted October 04, 2013.

DOI: 10.5935/abc.20140008

### References

1. Dores H, Abecasis J, Correia MJ, Gandara F, Fonseca C, Azevedo J, et al. Detecção de cardiotoxicidade subclínica induzida por trastuzumabe em portadoras de câncer de mama. *Arq Bras Cardiol.* 2013;100(4):328-32.
2. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. *Ann Oncol.* 2012;23 Suppl 7:vii155-66.
3. Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *J Natl Cancer Inst.* 2012;104(17):1293-305.
4. Kalil Filho R, Hajjar LA, Bacal F, Hoff PM, Diz M del P, Galas FR, et al. Diretriz Brasileira de cardio-oncologia da Sociedade Brasileira de Cardiologia. *Arq Bras Cardiol.* 2011;96(2 supl.1):1-52.